Article
Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.
All News
Article
The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few safety concerns.
Article
Dr. Jack Cush reviews the news, FDA approvals, and journal articles. In this episode: HMGCR Abs, FDA approvals and Cush eats crow.
Article
Medical University of South Carolina geneticist Betty Tsao, Ph.D., will lead a five-year project to identify rare mutations associated with childhood-onset systemic lupus erythematosus (SLE), or lupus, with more than $3.5 million in funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Tsao holds the Richard M. Silver Endowed Chair for Inflammation Research in the Division of Rheumatology and Immunology at MUSC.
Article
Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Pool therapy, Fibrosis, NSIE's and what's best for knee OA.
Article
Five patients with systemic lupus erythematosus (SLE) in China have been treated with a potentially groundbreaking form of chimeric antigen receptor (CAR) T-cell therapy, researchers reported, with encouraging results after 3 months.
Article
A systematic review and meta-analysis examined the role of high-resolution computed tomography (HRCT) in diagnosing and characterizing interstitial lung disease (ILD) associated with connective tissue diseases (CTDs).
Dr. John Cush
Tweet
Osteonecrosis: suspect with trauma, high-dose steroids, alcoholism, renal failure, transplantation, SLE, thrombotic states (e.g., sickle cell anemia, hemoglobinopathies), radiation injury, pancreatitis, gout, pregnancy, hyperlipidemia, & caisson disease (decompression sickness) https://t.co/y6iYd5fWZ2
Dr. John Cush
Tweet
Multimorbidity in SLE: metanalysis of 3 studies (1175 pts) saw Multimorbidity (by higher Charlson comorbidity index/CCI), is a strong independent predictor of mortality in SLE (OR 3.92). In SLE, the most freq comorbidities were DM, CVD, COPD, renal/lung/CNS Dz https://t.co/fuYUdfC6wE
Dr. John Cush
Tweet
Sequencing DNA to find new lupus treatments
MUSC geneticist Betty Tsao, Ph.D., will lead a five-year project to identify rare mutations associated with childhood-onset SLE, or lupus, with more than $3.5 million in funding from the National Institute of Arthritis and https://t.co/1vfQ4fK6FX
Dr. John Cush
Tweet
Prospective study of 62 lupus nephritis pts rx w/ induction therapy - MMF vs IV CYC x 6 mos followed by MMF for next 6 mos. At 1 year complete renal remission (CRR) seen in 77% MMF vs 29% CYC. https://t.co/wG2Qrn1PSU https://t.co/gP8XYO4q92
Dr. John Cush
Tweet
TREG EULAR 2025 - Review of SLE & Autoimmune Rheumatic Diseases (AIRD) https://t.co/8Em6Dp0oL5 via @YouTube
Dr. John Cush
Tweet
Report of 54 Sjögren dz pts w/ cutaneous vasculitis (CV); most had cryoglobulinemic vasculitis & hypergammaglob.vasculitis. Sjogrens w/ CV had higher risk of lymphoma. Type II cryoglob. vasculitis incr risk of mortality/lymphoma, renal dz, peripheral nerve involvement https://t.co/Yd1iu9ZJX0
Dr. John Cush
Tweet
QD Clinic: ILD with Positive SSA and Rash
Dr. Elena Joerns, Rochester, Minnesota discusses a case of ILD with positive SSA and rash, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/Yuz8CuIN5H https://t.co/3M9emsIXVf
Dr. John Cush
Tweet
CAR-T Product Shows Early Promise in Lupus
Five patients with systemic lupus erythematosus (SLE) in China have been treated with a potentially groundbreaking form of chimeric antigen receptor (CAR) T-cell therapy, researchers reported, with encouraging results after 3 months. https://t.co/eg37PZK6kn
Dr. John Cush
Tweet
Inception SLE study of 674 pts (without LN), mean age 34 yrs - 154 (23%) developed new proteinuria (LN) after median of 3.6 yr. Cumulative antimalarial exposure did NOT lower risk of LN (HR 0.98; 0.94-1.02); same for those w/ serologically active SLE (HR 0.97) https://t.co/8OU3yJAvhN
Dr. John Cush
Tweet
Should we be "scoring" comorbidity to predict outcomes? SLE metanalysis looked at Charlson Comorbidity index (CCI). 3 RCTs, 1175 SLE pts show higher CCI scores predicts increased all-cause mortality (OR 3.92(95% CI: 2.74–5.60) https://t.co/LXfsGo9iJq https://t.co/eK31lnFrJk
Dr. John Cush
Tweet
Comparative Frequency of Systemic autoimmune rheumatic diseases (SARDs) in Australia:
- SLE 57.9 per 100K
- Lupus nephritis 11.2 per 100K
- SSc 25.6 per 100K
- ANCA-associated vasculitis 10.8 per million PYs https://t.co/cx9LvswQ2E https://t.co/ltcXCw23bI
Dr. John Cush
Tweet
Sucutaneous anifrolumab? Phase III TULIP-SC trial in SLE patients showed SC anifrolumab (Saphnelo) significantly reducted lupus disease activity compared to placebo. https://t.co/vvI2av2vAJ https://t.co/0V1wsmFk0N
NDT
Tweet
Optimal glucocorticoid therapy in lupus nephritis
🔓https://t.co/e6SjmOrRpw
➡️This review provides an in-depth analysis of glucocorticoid therapy for lupus nephritis, a severe manifestation of systemic lupus erythematosus that affects up to 51.7% of patients https://t.co/JftCQiFif1
